Artificial intelligence (AI) company Bay Labs announced the presentation of two studies assessing performance of the company’s deep learning software for cardiovascular imaging. The first evaluated the software when used by medical professionals with no prior ultrasound experience to acquire diagnostic-quality echocardiograms, and the second evaluated the fully automated calculation of ejection fraction (EF) with accuracy and increased reproducibility. Results from these studies will be presented at the American College of Cardiology (ACC) 68th Annual Scientific Session, March 16-18 in New Orleans.

Canon Medical Systems Europe B.V. introduced the all-new Aquilion Start computed tomography (CT) system to the European market at the 2019 European Congress of Radiology (ECR), Feb. 28-March 3 in Vienna, Austria. Featuring premium technologies based on Canon Medical’s Aquilion family, the new Aquilion Start will provide the opportunity for medical institutions to extend their radiology practice.

A team of researchers at the University of Washington announced they developed a new automated system for producing zirconium-89, a diagnostic radionuclide used for cancer tumor imaging.

The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new report from MEDraysintell, continuing a trend dating back to mid-2016. The report says this trend may change if particle therapy vendors are able to build a strong order book in 2019 and 2020.

An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's risk for heart problems in the months and years after treatment. However, this information is not always reported and is rarely acted upon in current practice, according to research being presented at the American College of Cardiology's 68th Annual Scientific Session, March 16-18 in New Orleans.

Genomic medicine company Lucence Diagnostics announced a new project to develop artificial intelligence (AI) algorithms for improving diagnosis and treatment of liver cancer. The goal is to combine the imaging and molecular data from liver cancer patients into smarter software tools that help physicians make better treatment decisions.Genomic medicine company Lucence Diagnostics announced a new project to develop artificial intelligence (AI) algorithms for improving diagnosis and treatment of liver cancer. The goal is to combine the imaging and molecular data from liver cancer patients into smarter software tools that help physicians make better treatment decisions.

Artificial intelligence (AI) startup company Paige.AI has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its AI designed to enhance the clinical diagnosis and treatment of cancer. It is the first such designation for AI in cancer diagnosis publicly announced by any company, according to Paige.AI.

March 8, 2019 — Imaging Technology News (ITN) was named a finalist in multiple categories across print, web and other ...